CIK 0001782223
- Emerging growth company
Pyxis Oncology, Inc.
Sign in to watch- Ticker
- PYXS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831160910
- Phone
- +1 617-221-9059
- Business address
- 321 HARRISON AVENUE, BOSTON, MA, 02118
- 4 Open-market sale President and CEO sold 27,917 shares at an average $2.27 ($63,301)
- 4 Grant or award CFO and COO acquired 187,793 shares (grant or award)
- 4 Grant or award Chief Accounting Officer acquired 93,896 shares (grant or award)
- 4 Grant or award President and CEO acquired 469,483 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Grant or award President and CEO acquired 703,379 shares (grant or award)
- 4 Grant or award CFO and COO acquired 209,803 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 209,803 shares (grant or award)
- 4 Grant or award Chief Accounting Officer acquired 74,393 shares (grant or award)
- 4 Grant or award Director acquired 139,355 shares (grant or award)
- 4 Grant or award Director acquired 58,064 shares (grant or award)
- 4 Grant or award Director acquired 139,355 shares (grant or award)
- 4 Grant or award Director acquired 139,355 shares (grant or award)
- 4 Grant or award Director acquired 139,355 shares (grant or award)
- 4/A Open-market buy 10% owner bought 1,811,594 shares at $2.76 ($4,999,999)
- 4 Open-market buy 10% owner bought 1,811,594 shares at $2.76 ($4,999,999)
- 4 Grant or award Chief Executive Officer acquired 95,684 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 53,931 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 43,493 shares (grant or award)
Page 4 of 7 · 126 filings